Stock events for Acadia Healthcare Co., Inc. (ACHC)
Acadia Healthcare's stock price has been impacted by several events including the appointment of Debbie Osteen as CEO, the announcement of Q4 and full-year 2025 results, analyst rating changes, participation in investor conferences, stock performance and investor actions, and guidance and strategic focus. The company reported a 6.1% increase in Q4 revenue and a 5% increase for the full year 2025, exceeding prior guidance. However, a significant non-cash goodwill impairment charge of $996.2 million in Q4 2025 led to a net loss of $1.1 billion for the full year. Zacks Research upgraded Acadia Healthcare from a "strong sell" to a "hold" rating. The stock experienced a "brutal stretch" and was down as much as 60% in recent months, underperforming the S&P 500. One fund, Canyon Capital Advisors, fully exited its position in Acadia Healthcare in the fourth quarter of 2025, selling over 521,000 shares. In September 2025, then-CEO Chris Hunter acknowledged "incremental weaknesses" and underperforming facilities, leading to a $300 million cut in expected spending for 2026. The company also outlined plans to add 800-1,000 total beds in 2025 and 600-800 beds annually from 2026 to 2028.
Demand Seasonality affecting Acadia Healthcare Co., Inc.’s stock price
Demand for Acadia Healthcare's products and services exhibits some seasonality. Residential recovery and other inpatient facilities typically experience lower patient volumes and revenue during holidays. Child and adolescent facilities generally see lower patient volumes and revenue during the summer months, holidays, and other periods when school is not in session. In the first quarter of 2024, Acadia experienced weaker-than-anticipated patient volumes, which leadership primarily attributed to seasonality. The company's Q3 adjusted EBITDA is typically modestly above Q4, which is in line with typical seasonality.
Overview of Acadia Healthcare Co., Inc.’s business
Acadia Healthcare Company, Inc. (ACHC) is a leading provider of behavioral healthcare services in the United States and Puerto Rico, operating as a public entity within the S&P 600 index. The company offers a range of services through its facilities, including acute inpatient psychiatric facilities, specialty treatment facilities, Comprehensive Treatment Centers (CTCs), residential treatment centers, and outpatient programs. Acadia Healthcare generates revenue primarily from patient services, with payments largely coming from government programs and commercial insurance carriers.
ACHC’s Geographic footprint
Acadia Healthcare has a significant presence in the United States and Puerto Rico. As of March 2026, the company operated 262 treatment facilities across 39 states and Puerto Rico with around 11,850 beds. Historically, Acadia also operated in the United Kingdom through its subsidiary, Priory Group, but sold its UK operations in 2021 to refocus on the U.S. market.
ACHC Corporate Image Assessment
Acadia Healthcare's reputation has faced challenges, including allegations of abuse and scrutiny from federal lawmakers concerning its opioid treatment programs. These issues, alongside the underperformance of multiple facilities and facility closures, were acknowledged by the former CEO.
Ownership
Acadia Healthcare Company, Inc. has significant institutional ownership, with 243 institutional investors holding positions in ACHC as of December 2025. Major institutional owners include Wellington Management Group LLP, BlackRock, Inc., and The Vanguard Group, Inc. Reeve B. Waud is a significant individual shareholder, owning 16.15% of the company's shares.
